Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18753404 | 0.83 | KDM4E (0.48) | KDM4EMMP2TSHRLMNASMN1; SMN2 | |
| SCHEMBL20931572 | 0.81 | MEN1 (0.48) | KDM4EMMP2TSHRLMNASMN1; SMN2 | |
| SCHEMBL19767464 | 0.81 | LMNA (0.50) | KDM4EMMP2TSHRLMNASMN1; SMN2 | |
| SCHEMBL12074320 | 0.79 | MMP2 (0.56) | KDM4EMMP2TSHRLMNASMN1; SMN2 | |
| SCHEMBL30592746 | 0.79 | MMP2 (0.56) | KDM4EMMP2TSHRLMNASMN1; SMN2 | |
| SCHEMBL4148271 | 0.78 | MMP2 (0.60) | KDM4EMMP2TSHRLMNASMN1; SMN2 | |
| SCHEMBL18455545 | 0.77 | CCR1 (0.54) | KDM4EMMP2TSHRLMNASMN1; SMN2 | |
| SCHEMBL20999916 | 0.77 | KDM4E (0.54) | KDM4EMMP2TSHRLMNASMN1; SMN2 | |
| SCHEMBL12386952 | 0.77 | LMNA (0.54) | KDM4EMMP2TSHRLMNASMN1; SMN2 | |
| SCHEMBL12970139 | 0.77 | FABP1 (0.56) | KDM4EMMP2TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708169-A1 | 2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY | Agios Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20030171304-A1 | Pyridine-2-yl-aminoalkyl carbonyl glycyl-$g(b)-alanine and derivatives thereof | MERCK PATENT GMBH (DE) | 2003-09-11 | — | — | US | disclosed |
| CN-1436196-A | Pyridin-2-yl-aminoalkylcarbonylglycyl-beta-alanine and derivatives thereof | MERCK PATENT GMBH (DE) | 2003-08-13 | — | — | CN | disclosed |
| EP-1290010-A1 | PYRIDINE-2-YL-AMINOALKYL CARBONYL GLYCYL-$G(B)-ALANINE AND DERIVATIVES THEREOF | MERCK PATENT GmbH (DE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096365-A1 | PYRIDINE-2-YL-AMINOALKYL CARBONYL GLYCYL-$G(B)-ALANINE AND DERIVATIVES THEREOF | MERCK PATENT GMBH (DE) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171304-A1 | Pyridine-2-yl-aminoalkyl carbonyl glycyl-$g(b)-alanine and derivatives thereof | GLRB, GLRA3, HAO2 | KDM4E 4682/4885MMP2 3597/4885TSHR 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.